clairop

Can Fecal Calprotectin Be Normal With Crohn's?

Yes. Fecal calprotectin can be normal with active Crohn's, especially in the small bowel. Why it misses, which numbers matter, and what tests come next.

Clairop Team22 min read

Photo: Gabriel Cox / Unsplash

The short answer

Yes. A normal fecal calprotectin makes active inflammation in the colon unlikely, but it can miss Crohn's disease, particularly when the disease sits in the small bowel. Sensitivity falls the further up the small bowel the inflammation lies. If symptoms persist, guidelines point to imaging, capsule endoscopy or ileocolonoscopy rather than reassurance from one stool test.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

Yes, a fecal calprotectin can be normal when you have Crohn's disease. Calprotectin is a protein released by white blood cells in inflamed bowel, and it tracks inflammation in the colon well. It tracks inflammation in the small bowel less well, so Crohn's that sits only in the small intestine, mild patchy disease or a badly timed sample can all produce a normal number. For how calprotectin fits into long-term monitoring of mild disease, see can Crohn's disease stay mild long term.

That is the short answer, and it is the one many people in r/CrohnsDisease are circling when they post that their calprotectin and CRP came back normal while they still have the symptoms. This guide gives the longer version: how often it misses, why location matters so much, which cutoffs people mean by "normal", what a normal result does and does not rule out, and the test ladder doctors use when the numbers and the person do not agree.

Can you have Crohn's disease with a normal fecal calprotectin?

You can. Fecal calprotectin is a strong marker of colonic inflammation but a weaker marker of small bowel inflammation, so Crohn's confined to the small bowel can sit behind a normal result. In a pooled analysis of capsule endoscopy studies, calprotectin at a 200 microgram per gram cutoff caught only 42% of active small bowel disease (Kopylov 2016).

Calprotectin is a calcium-binding protein found in large amounts inside neutrophils. When those cells cross an inflamed bowel lining and break down, calprotectin ends up in stool, where a lab can measure it. That is the whole principle. It is a headcount of a particular type of white blood cell in the bowel, and it works best when most of the inflamed gut is close to the end of the line.

Crohn's disease can affect any part of the digestive tract, including the terminal ileum, the last stretch of small bowel before the colon. Some people have disease in the small bowel only. For them, the number that doctors lean on for ulcerative colitis can be less trustworthy, and the rest of this guide is about how much less, and what to do about it.

If you are mainly here because you have an unexpectedly high number rather than a low one, our guide to high calprotectin with no symptoms covers that mirror-image problem, and what calprotectin levels mean for ulcerative colitis covers the colon-only picture.

How accurate is calprotectin for Crohn's disease?

Across 13 studies pooled in a meta-analysis, calprotectin separated active from inactive Crohn's with an area under the curve of 0.88, slightly below 0.93 for ulcerative colitis. That is good but not perfect, and the figure hides a lot of variation between people with colonic disease and people with small bowel disease (Lin 2014).

An area under the curve of 0.88 means that if you picked one person with active Crohn's and one person in remission at random, the test would rank them correctly about 88% of the time. A figure of 1.0 would be a perfect test and 0.5 would be a coin toss. The same analysis found that calprotectin may have greater ability to assess disease activity in ulcerative colitis than in Crohn's.

A second, larger pooled analysis of 19 studies and 2,499 people with symptoms of active IBD reached the same conclusion from a different angle. It reported that calprotectin was more sensitive in ulcerative colitis than in Crohn's, with an overall sensitivity of 0.88 and specificity of 0.73 for endoscopic activity across IBD (Mosli 2015). Those are averages. They describe a population, not your result.

Why is calprotectin lower in small bowel Crohn's?

Nobody has fully explained it, but the pattern is clear. In a post-hoc analysis of 214 people with Crohn's who had both calprotectin and capsule endoscopy, median calprotectin rose from 63 micrograms per gram in the proximal small bowel to 190 in the distal small bowel to 542 when the colon was involved, for similar inflammatory scores (Ukashi 2025).

The authors of that study describe calprotectin as a topographical marker, one whose sensitivity increases the further down the gut the inflammation is. In plain terms, the nearer the inflamed tissue is to the exit, the more of its calprotectin arrives in your sample. The more proximal the disease, the more it can be diluted or altered on the way down. Dilution is a common suggestion in the literature, but this study measured the gradient rather than proving a cause, so treat the mechanism as a reasonable guess.

An older Finnish study of 87 ileocolonoscopies saw the same split from the other direction. Calprotectin correlated significantly with endoscopic scores in the colon, in ileocolonic or colonic disease, but ileal endoscopic scores and ileal biopsy findings failed to correlate with the stool markers (Sipponen 2008). The same study found a normal fecal marker was a reliable surrogate for inactive disease in people whose Crohn's involved the colon.

That last point is worth pausing on, because it explains why this question gets such different answers online. A normal calprotectin is genuinely reassuring when your Crohn's lives in the colon. It is least reassuring when your Crohn's lives in the small bowel, especially the upper part.

Does the cutoff change whether calprotectin is "normal"?

Yes, and by a lot. For small bowel Crohn's on capsule endoscopy, sensitivity was 0.83 at a cutoff of 50 micrograms per gram, 0.68 at 100 and 0.42 at 200, while specificity moved the other way, 0.53, 0.71 and 0.94 (Kopylov 2016). A "normal" at 200 is a much weaker statement than a "normal" at 50.

The table below pulls together the published figures that come up most when people ask whether their result counts as normal.

SettingCutoff (micrograms per gram)What was reported
Small bowel Crohn's, capsule endoscopy, all studies50Sensitivity 0.83, specificity 0.53
Small bowel Crohn's, capsule endoscopy, all studies100Sensitivity 0.68, specificity 0.71
Small bowel Crohn's, capsule endoscopy, all studies200Sensitivity 0.42, specificity 0.94
Suspected Crohn's only, capsule endoscopy50Sensitivity 0.89, negative predictive value 91.8%
Updated meta-analysis of 14 studies100Sensitivity 0.73, specificity 0.73 (best overall balance)
Proximal small bowel inflammation only77Best cutoff for mild inflammation in one study
Distal small bowel inflammation only123Best cutoff for mild inflammation in one study
People in symptomatic remission150 with a normal CRPAGA says this rules out active inflammation

Sources for the table: Kopylov 2016, Jung 2021, Ukashi 2025 and Ananthakrishnan 2023.

Three things stand out. First, no single cutoff works for everyone. A cutoff low enough to catch most small bowel disease also flags many people who do not have it, which is why labs and guidelines use different lines for different questions. Second, the lines that suit someone with colonic disease are too high for someone with proximal small bowel disease. Third, a result "in the normal range" on your lab report is not the same as "a result that excludes Crohn's in your situation".

A 2021 update of the capsule endoscopy analysis, covering 14 studies, suggested 100 micrograms per gram as the best-balanced cutoff for screening for small bowel Crohn's (Jung 2021). That is a research suggestion about balance, not a rule that everyone with a result under 100 is clear.

What does a normal result actually rule out?

A normal calprotectin makes active inflammation in the colon unlikely, and in people with suspected Crohn's, a result under 50 micrograms per gram carried a negative predictive value of 91.8% for small bowel disease on capsule endoscopy. It does not give the same assurance when the disease is mild, patchy or high in the small bowel.

The 91.8% figure comes from the subset of studies that included people with suspected, not established, Crohn's. The authors concluded that in patients with suspected Crohn's and a calprotectin under 50, the likelihood of a positive diagnosis is very low (Kopylov 2016). Notice what that does and does not say. It says very low, not zero, and it applies to a strict cutoff, not to every result below your lab's reference range.

For people who already have a diagnosis, the American Gastroenterological Association is more specific. In people in symptomatic remission, a fecal calprotectin under 150 micrograms per gram together with a normal CRP rules out active inflammation, and endoscopy to assess disease activity can be avoided. The same guideline says that in people with mild symptoms, neither a normal nor an elevated biomarker alone is accurate enough to decide whether the disease is active. After surgery, for low-risk people on medication to prevent recurrence, a normal calprotectin reliably rules out endoscopic recurrence (Ananthakrishnan 2023; see also Wright 2015).

So the honest framing is that a normal result is a useful piece of evidence in some situations and a weak one in others. It matters which situation is yours: suspected versus established disease, colon versus small bowel, remission versus symptoms, before surgery versus after it.

Is a normal CRP more reassuring than a normal calprotectin?

No. In 19 pooled studies of people with symptomatic IBD, CRP detected only 49% of endoscopic activity, against 88% for calprotectin, though CRP was more specific at 0.92. A normal CRP is therefore a weaker all-clear than a normal calprotectin, and the two together are not a guarantee (Mosli 2015).

CRP is a protein made by the liver in response to inflammation anywhere in the body. It is a blunt tool for the bowel. Many people with active Crohn's, especially mild or localized disease, have a normal CRP. One study of 104 people with Crohn's who had a colonoscopy and small bowel imaging within two weeks found that active disease at colonoscopy was associated with a raised CRP, but an abnormal small bowel scan was not significantly associated with it (Solem 2005).

In the capsule endoscopy gradient study, the magnitude of CRP elevation was unrelated to where along the small bowel the inflammation sat, unlike calprotectin (Ukashi 2025). So the idea that "my calprotectin was normal but at least my CRP would have caught it" does not hold up. Both can be normal while Crohn's is active. That is the pattern many people in r/CrohnsDisease describe: textbook symptoms, normal bloods, normal stool tests, and a diagnosis that only arrives after a scope, scan or capsule.

What do Reddit threads say about normal calprotectin and Crohn's?

The thread titles in r/CrohnsDisease show the pattern. People ask about their experience of a normal result and the wait that follows: a thread on whether anyone got a normal calprotectin and still had Crohn's, another asking whether two negative calprotectin tests make a colonoscopy the right next test, and one from someone with low calprotectin, a negative autoimmune panel and a colonoscopy wondering what else could be going on.

Community posts are not evidence for a medical fact, and nobody in those threads can tell you what your result means. What the titles show is how often the gap between how someone feels and what a stool test says becomes the main question. That gap is the reason this post exists. The research above says the gap is real and has a physical explanation, which is useful to know before an appointment.

Some posts also describe a small bowel finding turning up on a different test, such as a capsule or an MR enterography, after other results looked normal. That fits what the research above would predict for disease beyond the reach of a colonoscope, which is covered in our guide to whether you can have IBD with a clean colonoscopy.

What tests come next when calprotectin is normal but symptoms persist?

When symptoms persist despite a normal calprotectin, the usual next steps are an ileocolonoscopy with biopsies and cross-sectional imaging of the small bowel, such as MR enterography or intestinal ultrasound. Capsule endoscopy can follow if there is no known stricture. The right order depends on your history and local availability, so ask your gastroenterologist. Persistent symptoms with reassuring tests in quiet Crohn's are covered in IBS-like symptoms in Crohn's remission.

Here is how the main options compare. This is a general summary, not advice for any one person.

TestWhat it looks atMain strengthMain limit
Ileocolonoscopy with biopsiesColon and terminal ileum, with tissue samplesDirect view and biopsiesCannot reach most of the small bowel
MR enterographyWhole small bowel wall and surrounding tissueHigh accuracy, no radiationNeeds a scanner and prep, takes time
CT enterographyWhole small bowel wall and complicationsFast and widely availableRadiation exposure
Intestinal ultrasoundBowel wall thickness and blood flowNon-invasive, repeatableLess accurate above the terminal ileum
Capsule endoscopyLining of the small bowelDirect view of the liningA known narrowing can make it unsafe, so ask your team

A systematic review of 68 imaging studies found that ultrasound had a sensitivity of 0.84 and a specificity of 0.92 for assessing Crohn's activity, though its accuracy is lower for disease proximal to the terminal ileum. MRI had a sensitivity of 0.93 and a specificity of 0.90, and was less dependent on the examiner and the disease location. CT had similar accuracy to MRI. The review recommended preferring ultrasound or MRI over CT, particularly in young people, because of radiation (Panes 2011).

For a stricture or narrowing, a global consensus statement says cross-sectional imaging is required for accurate diagnosis and recommended before treatment decisions (Bettenworth 2024). Ask your team how they sequence tests, because a known narrowing can affect which ones are safe.

If you want to know what each one involves, we have plain-language guides to what to expect during an MRI enterography, what to expect during a capsule endoscopy and how intestinal ultrasound compares with colonoscopy in Crohn's.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Why can calprotectin and symptoms disagree in Crohn's?

They disagree because they measure different things. Calprotectin counts neutrophils in the gut lining, while symptoms come from how much bowel is involved, where it is, how fast things move, how sensitive your gut nerves are and whether scarring or narrowing is present. The two can drift apart in either direction.

The AGA's Crohn's guideline reflects this directly. It suggests that people in symptomatic remission are monitored with a biomarker and symptoms together rather than symptoms alone, and it notes that discordance between symptom assessment and biomarker value may merit endoscopic evaluation to confirm disease activity (Ananthakrishnan 2023). The international treat-to-target consensus, STRIDE-II, similarly lists symptom relief and normalization of serum and fecal markers as short-term targets, with endoscopic healing as a long-term target (Turner 2021).

Two practical patterns follow. One is the person who feels fine with a high calprotectin, covered in our guide to high calprotectin with no symptoms. The other is the person in this post: symptoms with a normal calprotectin. The second pattern has several possible explanations, and not all of them are active inflammation:

  • Active small bowel Crohn's that the stool test is not sensitive to.
  • Narrowing or scarring from past inflammation, which can cause pain or obstruction symptoms without a high inflammatory marker.
  • Other gut problems that can overlap with Crohn's, such as bile acid malabsorption, small intestinal bacterial overgrowth or lactose intolerance, which your doctor can test for separately.
  • Gut hypersensitivity or irritable-bowel-type symptoms alongside IBD.
  • Other conditions that mimic Crohn's, including celiac disease and infection.

That list is for discussing with your gastroenterologist, not for self-diagnosis. The point is that a normal calprotectin with symptoms is a prompt to look further, not a verdict that nothing is wrong.

Can calprotectin be normal when Crohn's is in the colon?

It is less likely. In ileocolonic and colonic Crohn's, calprotectin correlated significantly with colonic endoscopic scores, and a normal marker was a reliable surrogate for inactive disease (Sipponen 2008). Mild, patchy or very recent disease, and sampling and lab differences, can still produce a normal result.

Another source of confusion is that calprotectin tests can vary between assays and labs, so numbers are not always comparable. A further one is timing: a result from weeks before a flare, or from a different part of the day, can tell a different story from one taken at the worst point. If your numbers seem to contradict how you feel, ask whether the test is likely to be representative and whether a repeat is sensible, which our guide to how long calprotectin results take covers from a practical angle.

Does location change what the number means for treatment decisions?

Location matters for interpretation but, in one large cohort, a raised calprotectin predicted progression regardless of it. In 918 people with Crohn's followed for a median of about 50 months, a calprotectin of 115 micrograms per gram or higher identified people who went on to progress, with a hazard ratio of 2.4, independent of symptoms or disease location (Kennedy 2019).

Read that carefully. It says a raised result is informative whatever the location. It does not say a low result clears everyone, and the study was retrospective at a single tertiary center. It is a reason to take a raised calprotectin seriously even in disease that is partly small bowel, not a reason to treat a normal one as definitive.

What if calprotectin is normal but you have had Crohn's for years?

If you already have Crohn's and a normal calprotectin, it can be a good sign, but guidelines pair it with symptoms and a normal CRP, and they treat the picture differently depending on where your disease sits and how you feel. If symptoms and results disagree, the next step is a conversation about direct assessment, not a decision on the number alone.

In people with established Crohn's, regular monitoring with calprotectin is common. In the post-surgical setting, one prospective trial analysis found calprotectin had enough sensitivity and negative predictive value to monitor for recurrence after resection and predicted recurrence better than CRP or symptom scores (Wright 2015). That works partly because the rest of the colon, where calprotectin is most sensitive, is often still in place.

If your disease has mostly been in the small bowel, ask your team directly: "How reliable is calprotectin for me, given where my Crohn's is?" The answer shapes how much weight a single normal result should carry, and whether an occasional scan or ultrasound should be part of your monitoring plan. Do not change any medicine because of a normal result without discussing it with the prescriber.

Is the calprotectin test less reliable in some settings?

Yes. A systematic review of fecal calprotectin for detecting IBD in people with chronic abdominal symptoms found that sensitivity appears lower in primary care than in specialist settings and falls further at a 100 microgram per gram cutoff. The authors concluded that conclusive estimates for primary care were still missing (Freeman 2019).

That review is about detecting IBD in the first place, not monitoring known Crohn's, so it addresses a slightly different question. It is still useful context. It reminds us that the test's headline accuracy figures come mostly from specialist studies and that a single result in a general practice setting should be read with some humility.

How should you track symptoms when tests keep coming back normal?

Keep a dated log of stool frequency, night-time bowel movements, pain, weight and fatigue next to every test date and result. When markers are normal but you feel unwell, a clear record is what lets a doctor see a pattern and consider direct assessment rather than reading each result in isolation.

A good log for this situation is short. Each day note how many bowel movements you had, whether any woke you at night, pain on a simple 0 to 10 scale, any visible blood, and a one-word energy rating. Add your weight weekly if you can. Beside it, keep a second list: every calprotectin and CRP result with the date, the lab and the units. Bring both to the appointment.

That does two things. It turns "I feel unwell but my tests are normal" into something concrete, such as "night-time stools on 11 of the last 14 nights, 3 kilograms lost since spring, calprotectin under 50 twice". It also helps you and your doctor tell the difference between a persistent pattern and a bad week. Our guide on how to prepare for a GI doctor appointment has more on what to bring. A symptom tracker such as Clairop, which is free to download, can keep the log and produce a summary for the appointment; see how it works. You can also compare options in our best apps for Crohn's disease.

What should you ask your doctor if your calprotectin is normal?

Ask where your Crohn's is, how reliable calprotectin is for that location, and what test would answer the question if symptoms continue. Bring the list below. It is a set of questions to raise, not a checklist of tests you should demand.

  • Where is my Crohn's, or where is it suspected to be, and how well does calprotectin reflect inflammation there?
  • Which cutoff does this lab use, and was this result a fresh sample from a symptomatic period?
  • Would an MR enterography, intestinal ultrasound or capsule endoscopy tell us more than another stool test?
  • Is there any chance of a narrowing, and does that affect which tests are safe?
  • Could part of what I am feeling come from something other than active inflammation, and how would we check?
  • If my symptoms continue, what is the plan and by when?

What are the myths about normal calprotectin and Crohn's?

"A normal calprotectin rules out Crohn's." It does not. Sensitivity for small bowel disease was only 0.42 at a 200 microgram per gram cutoff (Kopylov 2016).

"A normal CRP means I am fine." CRP was less sensitive than calprotectin, at 0.49 against 0.88, in a pooled analysis of 2,499 people (Mosli 2015).

"If my colon looks clean, my Crohn's is quiet." A colonoscopy reaches the colon and the last stretch of small bowel, not most of the small bowel.

"Calprotectin never helps in small bowel disease." It does carry information: a result of 76 micrograms per gram or more was associated with appreciable inflammation on capsule endoscopy in people whose earlier workup was negative, though the overall correlation was weak (Koulaouzidis 2016).

"Normal tests mean it is all in my head." Calprotectin and CRP measure particular kinds of inflammation. They do not measure everything that can make someone feel unwell.

When should you see a doctor promptly?

See a doctor promptly if you have blood in your stool, unexplained weight loss, a fever, night-time diarrhea or pain, persistent vomiting, severe abdominal pain or a swollen abdomen, or symptoms that are worsening despite normal tests. Seek urgent care for severe pain with vomiting or if you cannot pass gas or stool.

These can signal active disease, a stricture or another complication, and a normal calprotectin does not make them safe to wait out. Tell your team about any new symptom, especially one that wakes you at night.

The honest bottom line

A normal fecal calprotectin is a useful piece of evidence and not a verdict. It is most reassuring in the colon and for people in symptomatic remission, and it is least reassuring in the small bowel and in people who still feel unwell. If your symptoms continue after normal tests, the evidence points to looking directly, with ileocolonoscopy, imaging or capsule endoscopy, rather than repeating a stool test and hoping.

You are not being difficult by asking. The pooled research says calprotectin misses a meaningful share of small bowel Crohn's, and CRP misses more. Bring dated symptoms, dated results and the questions above, and ask what the next test is if the answer is still "we do not know". This article is general information, not medical advice, and no result here replaces a conversation with your own gastroenterologist.

Frequently asked questions

Can you have Crohn's disease with a normal fecal calprotectin?
Yes. Fecal calprotectin is a sensitive marker of inflammation in the colon but a weaker one in the small bowel. In a meta-analysis of capsule endoscopy studies, calprotectin at a 200 microgram per gram cutoff caught only 42% of active small bowel Crohn's. A normal result lowers the odds but does not close the question.
How accurate is fecal calprotectin for Crohn's disease?
In a pooled analysis of 13 studies, calprotectin separated active from inactive Crohn's with an area under the curve of 0.88, a little lower than for ulcerative colitis at 0.93. At a 50 microgram per gram cutoff, sensitivity across all IBD was 0.92 with specificity 0.60. Numbers vary with where the disease sits.
Why is calprotectin lower in small bowel Crohn's?
Nobody has fully settled why. What is measured is that, for the same degree of small bowel inflammation on capsule endoscopy, median calprotectin was 63 in the proximal small bowel, 190 in the distal small bowel and 542 once the colon was involved. Dilution along a longer transit is a common suggestion, not a proven mechanism.
What cutoff makes calprotectin 'normal' in Crohn's disease?
It depends on the question. The AGA says a result under 150 micrograms per gram with a normal CRP rules out active inflammation in people in symptomatic remission. In suspected small bowel Crohn's, one meta-analysis found under 50 had a negative predictive value of 91.8%. Labs and assays differ, so use your own lab's range.
My calprotectin and CRP are both normal but I still have symptoms. What next?
Normal results make some kinds of active inflammation less likely, not impossible. Reasonable next steps to raise with your gastroenterologist are an ileocolonoscopy with biopsies, cross-sectional imaging such as MR enterography or intestinal ultrasound, or capsule endoscopy if there is no stricture. Symptoms can also have non-inflammatory causes that are worth looking for.
Can calprotectin be low while Crohn's is active in the colon?
It is uncommon but not impossible. Calprotectin correlates well with colonic endoscopic activity, and one study found a normal marker was a reliable sign of inactive disease in ileocolonic or colonic Crohn's. Mild or patchy disease, a poorly timed sample and lab differences can still produce a normal result, so symptoms that persist deserve a second look.
Is a normal CRP more reassuring than a normal calprotectin in Crohn's?
No. In a pooled analysis of 19 studies in symptomatic IBD, CRP sensitivity for endoscopic activity was only 0.49 against 0.88 for calprotectin. CRP rises less reliably in mild or localized disease, and in one study an abnormal small bowel scan was not associated with a raised CRP.
Does a normal calprotectin mean I do not need a colonoscopy or scan?
Not if symptoms persist. Guidelines treat calprotectin as one piece of the picture. The AGA notes that for people with mild symptoms neither a normal nor an elevated biomarker is accurate enough on its own to decide whether Crohn's is active, so a mismatch between symptoms and markers can merit direct assessment.
What is the best way to keep track of symptoms when tests keep coming back normal?
A dated log of stool frequency, night-time bowel movements, pain, weight and fatigue, kept alongside each test date and result, turns 'I feel unwell but my tests are normal' into evidence your doctor can act on. Any notes app or paper diary works. A symptom tracker such as Clairop can export a summary for appointments.

Sources

  1. Ananthakrishnan AN, Adler J, Chachu KA, Nguyen NH, Siddique SM, Weiss JM, et al. AGA clinical practice guideline on the role of biomarkers for the management of Crohn's disease. Gastroenterology. 2023;165(6):1367-99. doi:10.1053/j.gastro.2023.09.029
  2. Sipponen T, Karkkainen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008;28(10):1221-9. doi:10.1111/j.1365-2036.2008.03835.x
  3. Kopylov U, Yung DE, Engel T, Avni T, Battat R, Ben-Horin S, et al. Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2016;28(10):1137-44. doi:10.1097/MEG.0000000000000692
  4. Jung ES, Lee SP, Kae SH, Kim JH, Kim HS, Jang HJ. Diagnostic accuracy of fecal calprotectin for the detection of small bowel Crohn's disease through capsule endoscopy: an updated meta-analysis and systematic review. Gut Liver. 2021;15(5):732-41. doi:10.5009/gnl20249
  5. Koulaouzidis A, Sipponen T, Nemeth A, Makins R, Kopylov U, Nadler M, et al. Association between fecal calprotectin levels and small-bowel inflammation score in capsule endoscopy: a multicenter retrospective study. Dig Dis Sci. 2016;61(7):2033-40. doi:10.1007/s10620-016-4104-7
  6. Ukashi O, Kopylov U, Ungar B, Talan Asher A, Shachar E, Engel T, et al. Fecal calprotectin diagnostic level gradient along the small bowel in patients with Crohn's disease. J Crohns Colitis. 2025;19(1):jjae123. doi:10.1093/ecco-jcc/jjae123
  7. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(6):802-19. doi:10.1038/ajg.2015.120
  8. Lin JF, Chen JM, Zuo JH, Yu A, Xiao ZJ, Deng FH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20(8):1407-15. doi:10.1097/MIB.0000000000000057
  9. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(8):707-12. doi:10.1097/01.mib.0000173271.18319.53
  10. Panes J, Bouzas R, Chaparro M, Garcia-Sanchez V, Gisbert JP, Martinez de Guerenu B, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther. 2011;34(2):125-45. doi:10.1111/j.1365-2036.2011.04710.x
  11. Bettenworth D, Baker ME, Fletcher JG, Jairath V, Lu C, Bemelman W, et al. A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn's disease in clinical practice. Nat Rev Gastroenterol Hepatol. 2024;21(8):572-84. doi:10.1038/s41575-024-00935-y
  12. Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW. Association between level of fecal calprotectin and progression of Crohn's disease. Clin Gastroenterol Hepatol. 2019;17(11):2269-76.e4. doi:10.1016/j.cgh.2019.02.017
  13. Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology. 2015;148(5):938-47.e1. doi:10.1053/j.gastro.2015.01.026
  14. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD). Gastroenterology. 2021;160(5):1570-83. doi:10.1053/j.gastro.2020.12.031
  15. Freeman K, Willis BH, Fraser H, Taylor-Phillips S, Clarke A. Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy. BMJ Open. 2019;9(3):e027428. doi:10.1136/bmjopen-2018-027428

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools